Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06529419 · ClinicalTrials.gov registry record · Phase 2
A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 537
- Enrollment target
NCT06529419 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 537 participants.
The verdict
NCT06529419, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 537 participants
- Enrollment target
Study Summary
A dose range-finding study to assess the efficacy and safety of multiple dose levels of AZD8630 administered via a dry powder inhaler in adults with uncontrolled asthma at risk of exacerbations, receiving medium -to -high dose inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA).
Interventions
- DRUG Placebo
- DRUG AZD8630
- DEVICE Inhaler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 537 participants |
| Start Date | 2024-08-30 |
| Est. Completion | 2026-02-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06529419
The ClinicalTrials.gov registry entry for NCT06529419 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 537 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06529419 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06529419 about?
NCT06529419 is a clinical study titled "A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations". A dose range-finding study to assess the efficacy and safety of multiple dose levels of AZD8630 administered via a dry powder inhaler in adults with uncontrolled asthma at risk of exacerbations, receiving medium -to -high dose inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA).
What is the current status of trial NCT06529419?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 537 participants. The study started on 2024-08-30. Estimated completion is 2026-02-04.
What interventions are being tested in trial NCT06529419?
The interventions under investigation include: Placebo (DRUG), AZD8630 (DRUG), Inhaler (DEVICE).
Who is sponsoring clinical trial NCT06529419?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.